🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 32 of 116

  1. Aglatimagene besadenovec

    Candel Therapeutics

    Borderline Resectable Pancreatic Adenocarcinoma

    phase 2 mab active

    1 trial

  2. Albumin Paclitaxel

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  3. Aldesleukin

    Iovance Biotherapeutics B.V.

    Bone Sarcoma

    phase 2 mab active

    1 trial

  4. Alectinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Bone Cancer

    phase 2 small molecule active

    1 trial

  5. Alirocumab

    Regeneron UK Limited

    Non Small Cell Lung Cancer

    phase 2 small molecule on hold

    1 trial

  6. Alirocumab and Cemiplimab

    Regeneron UK Limited

    Non-small Cell Lung Cancer (NSCLC)

    phase 2 other active

    1 trial

  7. Alisertib

    Takeda

    Ovarian Carcinoma

    phase 2 small molecule completed

    2 trials

  8. Alisertib

    Takeda

    Diffuse Large B-cell Lymphoma

    phase 2 small molecule completed

    1 trial

  9. Alisertib

    PUMA BIOTECHNOLOGY, INC.

    Hormone Receptor Positive HER-2 Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  10. Alisertib

    Takeda

    Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  11. Alisertib

    PUMA BIOTECHNOLOGY, INC.

    Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  12. Alisertib

    PUMA BIOTECHNOLOGY, INC.

    Small Cell Lung Cancer ( SCLC )

    phase 2 small molecule active

    1 trial

  13. Alisertib

    Takeda

    Acute Myeloid Leukemia

    phase 2 small molecule completed

    1 trial

  14. Alisertib

    Takeda

    Acute Myelogenous Leukemia

    phase 2 small molecule completed

    1 trial

  15. Alisertib

    Takeda

    Adenocarcinoma of the Prostate

    phase 2 small molecule completed

    1 trial

  16. Alisertib (MLN8237)

    Takeda

    Diffuse Large B-Cell Lymphoma

    phase 2 small molecule completed

    1 trial

  17. Alitretinoin

    LIGAND PHARMACEUTICALS INC

    Sarcoma, Kaposi

    phase 2 small molecule completed

    2 trials

  18. Alkotinib Capsules

    Suzhou Zelgen Biopharmaceuticals Co.,Ltd

    ALK-positive Non-small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  19. Allogenic expanded Natural Killer Cells (AlloNK1)

    Hospital Authority, Hong Kong

    Nasopharyngeal Carcinoma (NPC)

    phase 2 mab active

    1 trial

  20. Almonertinib

    The First People's Hospital of Lianyungang

    EGFR Positive Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  21. Almonertinib

    The First People's Hospital of Lianyungang

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  22. Almonertinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Cancer Non-small Cell Stage IV

    phase 2 small molecule active

    1 trial

  23. Almonertinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  24. Almonertinib 110 MG

    Chinese University of Hong Kong

    Rare Tumor

    phase 2 small molecule active

    1 trial

  25. AloCelyvir

    The George Institute

    mEtastatic Uveal Melanoma

    phase 2 small molecule active

    1 trial

  26. Alpelisib

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  27. Alphagan 2 mg/ml colirio en solución, Brimonidine Tartrate 0.2% w/v Eye Drops., Mirvetuximab Soravtansine, Pred Forte 10 mg/ml colirio en suspensión, Pred Forte 1% w/v, Eye Drops Suspension

    AbbVie Deutschland GmbH & Co. KG

    Recurrent Ovarian Cancer with High Folate Receptor-Alpha Expression

    phase 2 small molecule active

    1 trial

  28. Amcenestrant

    Sanofi Pasteur

    Breast Cancer Metastatic

    phase 2 small molecule terminated

    1 trial

  29. Ametinib combined with bevacizumab

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  30. An Open-Label, Multi-Center, Phase Ib/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin (Plus A Single Pretreatment Dose of Obinutuzumab) in Adult Patients with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma

    Hoffmann-La Roche

    Relapsed/refractory (r/r) B-cell Non-Hodgkin’s Lymphoma (NHL)

    phase 2 other active

    1 trial

  31. An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate (ADC), in Previously Treated Subjects with HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer

    Eisai Co.,

    HER2 positive or HER2-low metastatic breast cancer

    phase 2 other active

    1 trial

  32. An Open-label, Phase I/II First-in-Human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumor Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants with Advanced Solid Tumors

    Ipsen

    Pancreatic Ductal Adenocarcinoma, Melanoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Solid tumors

    phase 2 other active

    1 trial

  33. Anlotinib

    The First People's Hospital of Lianyungang

    Non-Small-Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  34. Anlotinib and Sintilimab injection

    The First People's Hospital of Lianyungang

    Advanced Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  35. Anlotinib combined Docetaxel

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  36. Anlotinib plus Pemetrexed

    Henan Provincial People's Hospital

    Non-squamous Cell Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  37. Anlotinib+ Liposomal Doxorubicin

    The First People's Hospital of Lianyungang

    Sarcoma

    phase 2 small molecule active

    1 trial

  38. Anrotinib plus Tirelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  39. Anti-BCMA-CAR-transduced T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Leukemia

    phase 2 mab active

    1 trial

  40. Anti-CD19 CAR-T

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia ,Lymphomas

    phase 2 mab active

    1 trial

  41. Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lymphoma, Large B-Cell, Diffuse

    phase 2 mab active

    1 trial

  42. Anti-CD20-CAR-transduced T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Leukemia

    phase 2 mab active

    1 trial

  43. Anti-CD30-CAR-transduced T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Leukemia

    phase 2 mab active

    1 trial

  44. Anti-CD40 Agonist Monoclonal Antibody CDX-1140

    United Therapeutics Europe Ltd

    Ovarian Clear Cell Adenocarcinoma

    phase 2 mab active

    1 trial

  45. Anti-HER2 CAR-T

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer

    phase 2 mab terminated

    1 trial

  46. Anti-PD-1 antibody

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric or Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

  47. Anvumetostat

    Amgen

    Advanced MTAP-null Solid Tumors

    phase 2 small molecule active

    1 trial

  48. Apalutamide

    Janssen Cilag International NV

    Salivary Gland Neoplasms

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.